MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- ORCHID PHARMA LTD - MYLAN (US)
ORCHID PHARMA LTD vs MYLAN (US) - Comparison Results
ORCHID PHARMA LTD Change
Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 ORCHID PHARMA LTD  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ORCHID PHARMA LTD Sep-13 |
MYLAN Dec-18 |
ORCHID PHARMA LTD/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 194 | 3,366 | - | |
| Low | Rs | 35 | 1,853 | - | |
| Sales per share (Unadj.) | Rs | 276.5 | 1,548.7 | - | |
| Earnings per share (Unadj.) | Rs | -79.2 | 42.1 | - | |
| Cash flow per share (Unadj.) | Rs | -43.5 | 332.0 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 53.9 | 1,675.5 | - | |
| Shares outstanding (eoy) | m | 70.45 | 514.50 | - | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 0.4 | 1.7 | 24.6% | |
| Avg P/E ratio | x | -1.4 | 62.0 | -2.3% | |
| P/CF ratio (eoy) | x | -2.6 | 7.9 | -33.5% | |
| Price / Book Value ratio | x | 2.1 | 1.6 | 136.3% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 8,067 | 1,342,433 | 0.6% | |
| No. of employees | `000 | 2.8 | 35.0 | 8.0% | |
| Total wages/salary | Rs m | 2,527 | 0 | - | |
| Avg. sales/employee | Rs Th | 6,956.1 | 22,766.6 | 30.6% | |
| Avg. wages/employee | Rs Th | 902.5 | 0 | - | |
| Avg. net profit/employee | Rs Th | -1,993.0 | 618.2 | -322.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 19,477 | 796,831 | 2.4% | |
| Other income | Rs m | 407 | 0 | - | |
| Total revenues | Rs m | 19,884 | 796,831 | 2.5% | |
| Gross profit | Rs m | 1,103 | 206,190 | 0.5% | |
| Depreciation | Rs m | 2,519 | 149,198 | 1.7% | |
| Interest | Rs m | 5,227 | 38,325 | 13.6% | |
| Profit before tax | Rs m | -6,236 | 18,667 | -33.4% | |
| Minority Interest | Rs m | 20 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 511 | 0 | - | |
| Tax | Rs m | -125 | -2,970 | 4.2% | |
| Profit after tax | Rs m | -5,580 | 21,637 | -25.8% | |
| Gross profit margin | % | 5.7 | 25.9 | 21.9% | |
| Effective tax rate | % | 2.0 | -15.9 | -12.6% | |
| Net profit margin | % | -28.7 | 2.7 | -1,055.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,014 | 444,950 | 2.5% | |
| Current liabilities | Rs m | 32,060 | 324,417 | 9.9% | |
| Net working cap to sales | % | -108.1 | 15.1 | -714.4% | |
| Current ratio | x | 0.3 | 1.4 | 25.0% | |
| Inventory Days | Days | 95 | 84 | 113.5% | |
| Debtors Days | Days | 34 | 93 | 36.0% | |
| Net fixed assets | Rs m | 29,440 | 154,572 | 19.0% | |
| Share capital | Rs m | 705 | 424 | 166.1% | |
| Net worth | Rs m | 3,800 | 862,026 | 0.4% | |
| Long term debt | Rs m | 9,018 | 930,402 | 1.0% | |
| Total assets | Rs m | 46,510 | 2,312,288 | 2.0% | |
| Interest coverage | x | -0.2 | 1.5 | -13.0% | |
| Debt to equity ratio | x | 2.4 | 1.1 | 219.9% | |
| Sales to assets ratio | x | 0.4 | 0.3 | 121.5% | |
| Return on assets | % | -0.8 | 2.6 | -29.3% | |
| Return on equity | % | -146.9 | 2.5 | -5,850.6% | |
| Return on capital | % | -3.7 | 3.2 | -117.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,682 | 165,582 | 1.0% | |
| From Investments | Rs m | -9,860 | -85,587 | 11.5% | |
| From Financial Activity | Rs m | 6,644 | -77,138 | -8.6% | |
| Net Cashflow | Rs m | -1,535 | 1,372 | -111.9% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 70.71 Rs / USD
Compare ORCHID PHARMA LTD With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ORCHID PHARMA LTD With: NOVARTIS SANOFI INDIA DIVIS LABORATORIES ABBOTT INDIA SHASUN PHARMA
|
| |
Today's Market
Sensex Opens Firm; Metal Stocks Rally(09:30 am)
Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 1.2% while the Hang Seng is up 2.1%.
Related Views On News
ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)
Jan 31, 2019 | Updated on Jan 31, 2019For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)
Aug 24, 2018 | Updated on Aug 24, 2018For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Use My Secret to Increase Your Trading Profits Today
Dec 10, 2019What to do after every trade.
A Simple, 7-Step Checklist for Your Trading Success
Dec 4, 2019What we can learn from one of the greatest traders to have ever lived.
Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020 (Profit Hunter)
Dec 5, 2019This corner of the market could provide more returns than blue chips in 2020.
Make the Most of the Smallcap Rebound with These Stocks (Profit Hunter)
Dec 3, 2019Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
What Is the IPO Euphoria Signaling Us About the Markets? (The 5 Minute Wrapup)
Dec 2, 20192019 will be remembered as the year of great money-making IPOs...
More|
| |
ORCHID PHARMA LTD SHARE PRICE
Jul 24, 2019 (Close)
TRACK ORCHID PHARMA LTD
- Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ORCHID PHARMA LTD
ORCHID PHARMA LTD 8-QTR ANALYSIS
COMPARE ORCHID PHARMA LTD WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.